gene silencing Archives -

Gene silencing and mRNA: breakthroughs and barriers – the pharmaphorum podcast

On this week’s pharmaphorum podcast, editor in chief Jonah Comstock catches up with Dr. Marie Wikström Lindholm, SVP of molecular

Gene silencing and mRNA: breakthroughs and barriers – the pharmaphorum podcast

https://pharmaphorum.com/podcast/gene-silencing-mrna-breakthroughs-and-barriers/

Podcast/ R&D/ Slider in video/ Video/ Views & Analysis/ Views and analysis

Gene silencing and mRNA: breakthroughs and barriers – the pharmaphorum podcast

Jonah Comstock COVID-19, gene silencing, gene therapy, mRNA, Silence Therapeutics 0 Comment

On this week’s pharmaphorum podcast, editor in chief Jonah Comstock catches up with Dr. Marie Wikström Lindholm, SVP of molecular

Gene silencing and mRNA: breakthroughs and barriers – the pharmaphorum podcast

https://pharmaphorum.com/r-d/gene-silencing-and-mrna-breakthroughs-and-barriers/

News/ News/ R&D

Amgen eyes swift move to ph3 for cardiovascular drug olpasiran

Phil Taylor Amgen, atherosclerosis, gene silencing, lipoprotein(a), Novartis, olpasiran, pelacarsen, Silence Therapeutics, siRNA, SLN360 0 Comment

Amgen is planning to push its olpasiran candidate for reducing lipoprotein(a) into phase 3 as quickly as possible

Amgen eyes swift move to ph3 for cardiovascular drug olpasiran

https://pharmaphorum.com/news/amgen-eyes-swift-move-to-ph3-for-cardiovascular-drug-olpasiran/

News/ News/ R&D

Novo Nordisk snaps up RNAi partner Dicerna in $3.3bn takeover deal

Phil Taylor Dicerna, gene silencing, M&A, Novo Nordisk, RNAi 0 Comment

Danish drugmaker Novo Nordisk must like what it has seen in its two-year-old alliance with gene-silencing specialist Dicerna

Novo Nordisk snaps up RNAi partner Dicerna in $3.3bn takeover deal

https://pharmaphorum.com/news/novo-nordisk-snaps-up-rnai-partner-dicerna-in-3-3bn-takeover-deal/

Market Access/ News/ News

NICE backs NHS use of Novartis’ cholesterol drug Leqvio

Phil Taylor cholesterol, gene silencing, HEOR, inclisiran, Leqvio, market access, NHS, NICE, Novartis, RNAi 0 Comment

Novartis’ cholesterol-lowering drug Leqvio will be made available on the NHS in England and Wales, and could help

NICE backs NHS use of Novartis’ cholesterol drug Leqvio

https://pharmaphorum.com/news/nice-backs-nhs-use-of-novartis-cholesterol-drug-leqvio/

engineering and genetic editing through the Crispr technique. DNA chain breaking down. 3D rendering

News/ News/ Oncology

Cash round sets up trial of InteRNA’s microRNA for cancer

Phil Taylor financing, gene silencing, immuno-oncology, InteRNA Technologies, microRNA, Oncology, solid tumour 0 Comment

Dutch biotech InteRNA Technologies has raised €18.5 million ($22 million) in second-round financing as it prepares to start

Cash round sets up trial of InteRNA’s microRNA for cancer

https://pharmaphorum.com/news/cash-round-sets-up-trial-of-internas-microrna-for-cancer/

News/ News/ R&D

Novo Nordisk’s gene silencing alliance with Dicerna bears first fruit

Phil Taylor Diabetes, Dicerna, gene silencing, hepatology, NASH, Novo Nordisk, RNAi 0 Comment

Two years after starting to work together, Novo Nordisk and Dicerna have selected the first candidate from a

Novo Nordisk’s gene silencing alliance with Dicerna bears first fruit

https://pharmaphorum.com/news/novo-nordisks-gene-silencing-alliance-with-dicerna-bears-first-fruit/

News/ News/ R&D

New CEO Mortazavi takes UK biotech e-therapeutics into gene silencing

Richard Staines Biotech, e-Therapeutics, gene silencing, inflammation, people, R&D 0 Comment

UK biotech e-therapeutics has a new CEO, with executive chairman and former Silence Therapeutics chief Ali Mortazavi chosen

New CEO Mortazavi takes UK biotech e-therapeutics into gene silencing

https://pharmaphorum.com/news/new-ceo-mortazavi-takes-e-therapeutics-into-gene-silencing/

Podcast/ R&D/ Views & Analysis/ Views and analysis

Alnylam, gene-silencing and biotech in 2020: the pharmaphorum podcast

Dominic Tyer Alnylam, coronavirus, COVID-19, gene silencing, podcast, RNAi 0 Comment

Alnylam’s Brendan Martin joined the pharmaphorum podcast for episode 23 to talk about his company’s work in gene-silencing

Alnylam, gene-silencing and biotech in 2020: the pharmaphorum podcast

https://pharmaphorum.com/r-d/alnylam-gene-silencing-biotech-podcast/

Trending

gene silencing

Login